American Well Corporation (AMWL)
| Market Cap | 158.73M +39.3% |
| Revenue (ttm) | 237.38M -9.3% |
| Net Income | -87.88M |
| EPS | -5.40 |
| Shares Out | 16.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,031 |
| Open | 9.39 |
| Previous Close | 9.46 |
| Day's Range | 9.35 - 9.50 |
| 52-Week Range | 3.71 - 9.50 |
| Beta | 1.53 |
| Analysts | Hold |
| Price Target | 7.50 (-21.05%) |
| Earnings Date | May 5, 2026 |
About AMWL
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into th... [Read more]
Financial Performance
In 2025, American Well's revenue was $249.33 million, a decrease of -1.98% compared to the previous year's $254.36 million. Losses were -$95.70 million, -54.02% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AMWL stock is "Hold." The 12-month stock price target is $7.5, which is a decrease of -21.05% from the latest price.
News
Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an ...
American Well Transcript: 21st Annual Needham Technology, Media, & Consumer Conference
The company has transformed to focus on payer and government markets, achieving strong Q1 results with higher subscription and visit revenues, improved margins, and significant cost reductions. Major government contracts and payer renewals are set to drive growth and margin expansion, with AI adoption supporting further efficiencies.
Amwell® to Participate in Upcoming Investor Conference
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschho...
Amwell price target raised to $6.50 from $6 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amwell (AMWL) to $6.50 from $6 and keeps an Equal Weight rating on the shares. Revenue upside in the quarter and tighter…
Amwell price target raised to $8 from $5 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Amwell (AMWL) to $8 from $5 and keeps a Hold rating on the shares. The firm said the company…
American Well Earnings Call Transcript: Q1 2026
Revenue declined 18% year-over-year in Q1 2026, but gross margin remained strong and cost discipline led to a significant reduction in losses. Renewals and pipeline growth were robust, with confidence in achieving cash flow breakeven in Q4 and multi-year growth ahead.
American Well Earnings release: Q1 2026
American Well released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
American Well Quarterly report: Q1 2026
American Well has published its Q1 2026 quarterly earnings report on May 5, 2026.
Amwell® Announces Results for First Quarter 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results ...
American Well Proxy statement: Proxy filing
American Well filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
American Well Proxy statement: Proxy filing
American Well filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Amwell® to report first quarter 2026 operating results
BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report first quarter 2026 o...
American Well Transcript: TD Cowen 46th Annual Health Care Conference
Virtual healthcare is challenged by market fragmentation, but growth is driven by payer and government segments. Major contracts like Elevance and DHA support revenue stability, with AI integration enhancing efficiency. 2026 guidance targets $195–$205M revenue and EBITDA breakeven, with strong cash reserves and new government opportunities expected.
Amwell makes grant to new employee under inducement plan
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, announced that on February 18, A...
Amwell price target lowered to $5 from $7 at TD Cowen
TD Cowen analyst Charles Rhyee lowered the firm’s price target on Amwell (AMWL) to $5 from $7 and keeps a Hold rating on the shares. The firm said Q4 EBITDA…
Amwell price target lowered to $5 from $6 at Stifel
Stifel analyst David Grossman lowered the firm’s price target on Amwell (AMWL) to $5 from $6 and keeps a Hold rating on the shares. 2026 revenue guidance coming in about…
American Well Earnings Call Transcript: Q4 2025
2025 saw a strategic transformation to a unified tech platform, with divestitures and cost reductions leading to improved margins and a higher-quality revenue base. 2026 guidance projects lower revenue but improved profitability, with positive cash flow expected in Q4.
American Well Annual report: Q4 2025
American Well has published its Q4 2025 annual report on February 12, 2026.
American Well Earnings release: Q4 2025
American Well released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
Amwell® Announces Results for Fourth Quarter and Full Year 2025
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results...
Amwell® to report fourth quarter and full year 2025 operating results
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and fu...
Amwell price target lowered to $6 from $10.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Amwell (AMWL) to $6 from $10.50 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm…
Amwell price target lowered to $7 from $10 at TD Cowen
TD Cowen lowered the firm’s price target on Amwell (AMWL) to $7 from $10 and keeps a Hold rating on the shares. The firm said its 3Q adj. EBITDA beat/raise…
Amwell price target lowered to $6 from $8 at Stifel
Stifel lowered the firm’s price target on Amwell (AMWL) to $6 from $8 and keeps a Hold rating on the shares. While the company’s execution on cost takeout and the…
American Well Earnings Call Transcript: Q3 2025
Q3 revenue and adjusted EBITDA exceeded expectations, driven by higher subscription revenue, cost efficiencies, and a shift to a more software-focused model. The company is divesting non-core assets, investing in AI, and expects positive cash flow from operations by end of 2026.